News of Note—Bavarian Nordic, vaccine hesitancy and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> The U.S. government signed off on a $44 million option in its smallpox vaccine contract with Bavarian Nordic. Release

> WHO has named vaccine hesitancy and Ebola among its top 10 threats to global health in 2019. ABC News article

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> An Alzheimer's disease vaccine from United Neuroscience performed favorably in a phase 2 study, the biotech said. Bloomberg Businessweek article

> Valneva secured a $59 million contract with the U.S. Department of Defense to supply its Japanese encephalitis vaccine Ixiaro. Release

> CDMO Almac is expanding its capacity to manufacture personalized cancer vaccines. Outsourcing-Pharma article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.